Loading institutional data...
Loading institutional data...
Held by 186 of 5,944 reporting institutions (91th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $7.79 today, the market must believe free cash flow compounds -22.4%/yr for a decade (off $173M normalized FCF).
2-stage DCF · 0.08B shares · net debt -$145M
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
5/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $173M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 40%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 14-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 92.3 | 131.8 | 85.6 | 78.0 | 5.7 | — | 7.0 | 7.1 |
| Gross Profit | 7.7 | -31.8 | 14.4 | 22.0 | 94.3 | — | 92.7 | 88.5 |
| R&D | 4379.4 | 3902.0 | 5591.7 | 6878.2 | 16327.6 | — | 9.1 | 6.2 |
| SG&A | 1878.7 | 3482.6 | 5801.1 | 8561.3 | 30586.6 | — | 68.9 | 21.9 |
| Operating Income | -6250.4 | -7416.3 | -11378.4 | -15417.5 | -46819.9 | — | -51.4 | 48.2 |
| Income Tax | — | -1786.6 | -2160.8 | -654.8 | -895.3 | — | -3.2 | -4.2 |
| Net Income | -6242.4 | -5801.3 | -9207.7 | -14774.7 | -45409.9 | — | -41.2 | 52.3 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on CRMD: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $311.7M 100.0% | $43.5M 100.0% | — | $65K 100.0% | $191K 100.0% | $239K 100.0% | $283K 100.0% | $430K 100.0% | $329K 100.0% | $224K 100.0% |
| Cost of Revenue | $22.1M 7.1% | $3.0M 7.0% | — | $4K 5.7% | $149K 78.0% | $205K 85.6% | $373K 131.8% | $397K 92.3% | $115K 34.9% | $367K 163.6% |
| Gross Profit | $275.7M 88.5% | $40.3M 92.7% | — | $62K 94.3% | $42K 22.0% | $34K 14.4% | -$90K -31.8% | $33K 7.7% | $214K 65.1% | -$143K -63.6% |
| Research & Development | $19.3M 6.2% | $3.9M 9.1% | $13.2M | $10.7M 16327.6% | $13.1M 6878.2% | $13.4M 5591.7% | $11.1M 3902.0% | $18.8M 4379.4% | $24.5M 7435.2% | $15.7M 7021.4% |
| Selling, General & Admin | $68.2M 21.9% | $30.0M 68.9% | $35.8M | $20.0M 30586.6% | $16.3M 8561.3% | $13.9M 5801.1% | $9.9M 3482.6% | $8.1M 1878.7% | $8.7M 2627.3% | $8.9M 3963.8% |
| Total Operating Expenses | $125.6M 40.3% | $62.6M 144.1% | $49.0M | $30.7M 46914.2% | $29.5M 15439.5% | $27.3M 11392.8% | $20.9M 7384.5% | $26.9M 6258.1% | $33.1M 10062.5% | $24.6M 10985.2% |
| Operating Income | $150.1M 48.2% | -$22.4M -51.4% | -$49.0M | -$30.6M -46819.9% | -$29.4M -15417.5% | -$27.2M -11378.4% | -$21.0M -7416.3% | -$26.9M -6250.4% | -$32.9M -9997.4% | -$24.8M -11048.8% |
| Interest Expense | $2.8M 0.9% | $36K 0.1% | $34K | $27K 40.5% | $16K 8.3% | $33K 13.9% | $787K 278.0% | $2K 0.4% | $6K 1.7% | $1K 0.6% |
| Interest & Investment Income | $3.8M 1.2% | $2.6M 5.9% | $2.7M | $326K 498.4% | $14K 7.5% | $116K 48.5% | $323K 113.9% | $37K 8.5% | $111K 33.6% | $127K 56.6% |
| Other Income (Expense), net | -$125K -0.0% | $3.0M 7.0% | $2.6M | $337K 514.7% | -$23K -12.0% | $24K 9.9% | -$486K -171.6% | $35K 8.0% | -$86K -26.1% | — |
| Pretax Income | $150.0M 48.1% | -$19.3M -44.5% | -$46.3M | -$30.3M -46305.2% | -$29.5M -15429.5% | -$27.2M -11368.5% | -$21.5M -7587.9% | -$26.8M -6242.4% | -$33.0M -10023.5% | -$24.6M -10996.5% |
| Income Tax Expense | -$13.0M -4.2% | -$1.4M -3.2% | — | -$586K -895.3% | -$1.3M -654.8% | -$5.2M -2160.8% | -$5.1M -1786.6% | — | — | — |
| Net Income | $163.1M 52.3% | -$17.9M -41.2% | -$46.3M | -$29.7M -45409.9% | -$28.2M -14774.7% | -$22.0M -9207.7% | -$16.4M -5801.3% | -$26.8M -6242.4% | -$33.0M -10023.4% | -$24.6M -10996.5% |
| Per Share | ||||||||||
| EPS (Basic) | $2.25 | $-0.30 | $-0.91 | $-0.74 | $-0.75 | — | — | — | — | — |
| EPS (Diluted) | $2.04 | $-0.30 | $-0.91 | $-0.74 | $-0.75 | — | — | — | — | — |
| Weighted Avg Shares (Basic) | 72K | 59K | 50.9M | 40.3M | 37.7M | — | — | — | — | — |
| Weighted Avg Shares (Diluted) | 80K | 59K | 50.9M | 40.3M | 37.7M | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| CRMD | $617M | 3.8× | 3.1× | 2.0× | 617% | 88.5% | 52.3% | 40.2% | 40.2% | — | 186 |
Peers = companies sharing CRMD's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.